Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP, SynTracer+Flexibody+H3

English

WELCOME TO BIOSION

Biosion is a global biotechnology company that is currently in the clinical stage.

Biosion is a global clinical-stage biotechnology company focused on developing innovative antibody-based therapies to improve outcomes for patients with immune and oncologic diseases. Leveraging its proprietary technologies such as the H³ antibody discovery platform, SynTracer® HT endocytosis platform, and Flexibody® bispecific platform, Biosion creates highly differentiated medicines to address significant unmet medical needs worldwide.

PARTNERING

In Global For Global

NEWS

News and Information

Spot the chance with global eyes, Meet unmet needs where healing lies.

Professional quality

2022-08-12

Biosion next generation ADC platform will be presented at World ADC San Diego 2022

2022-08-12

Biosion next generation ADC platform will be presented at World ADC San Diego 2022

The 13th World ADC San Diego 2022 will be held from September 6 to 9. More than 600 ADC experts from around the world will attend the conference. Biosion will present the next-generation ADC development platform designed to identify the optimized antibodies with superior properties for ADCs. In rec

2022-04-06

Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

2022-04-06

Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

Biosion, Inc. (“Biosion”), a global R&D stage biotechnology company， announced today the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-060T: anti-siglec-15 antibody and BSI-082: anti-SIRP antibody, at the American Association for Cancer Research (AACR) Annual

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

Find us in China, the United States & Australia

Quick Links